Northwestern University Human Resources

- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1851-01-28
- Employees
- 5K
- Market Cap
- -
Clinical Trials
1.3k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1116 trials with phase data)• Click on a phase to view related trials
Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Cancer, ENLIGHT Trial
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- First Posted Date
- 2025-09-17
- Last Posted Date
- 2025-09-17
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 100
- Registration Number
- NCT07178301
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Valproic AcId for Traumatic BRAin INjury Trial
- Conditions
- Moderate Traumatic Brain Injury (TBI)Severe Traumatic Brain Injury
- Interventions
- Other: Standard of care treatment + normal salineDrug: Valproic Acid (VPA)
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 432
- Registration Number
- NCT07166393
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
🇺🇸University of Southern California, Los Angeles, California, United States
Personalized Theta-burst Stimulation for Long-lasting Changes in Approach/Avoidance Behavior
- Conditions
- Approach/Avoidance Behavior
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 26
- Registration Number
- NCT07161505
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
REmote Physical ACtivity Intervention for High Blood Pressure Postpartum
- Conditions
- Hypertension (HTN)Hypertension ,PregnancyPhysical Activity
- First Posted Date
- 2025-08-17
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 60
- Registration Number
- NCT07127731
Pediatricians Building Resilience Through Early Identification for Toddler Well-Being
- Conditions
- Mental Health
- First Posted Date
- 2025-07-29
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 432
- Registration Number
- NCT07091240
- Locations
- 🇺🇸
Nemours Children's Health, Wilmington, Delaware, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 269
- Next
News
Northwestern University Develops Novel Nanostructure to Triple CRISPR Gene Editing Efficiency
Northwestern University researchers have developed lipid nanoparticle spherical nucleic acids (LNP-SNAs) that deliver CRISPR gene-editing tools up to three times more effectively than standard methods.
FDA-Approved Asthma Drug Zileuton Shows Promise in Preventing Food Allergy Reactions
Northwestern Medicine researchers discovered that Zileuton, an FDA-approved asthma drug, nearly eliminated life-threatening allergic reactions in mice by blocking a previously unknown pathway involving the DPEP1 gene.
Nature Study Validates LIXTE's PP2A Inhibitor LB-100 for Enhanced Cancer Immunotherapy
A Nature study led by MD Anderson researchers found that ovarian cancer patients with PPP2R1A mutations had significantly better overall survival when treated with immune checkpoint blockade therapy.
Prometheus Laboratories Expands Precision-Guided Dosing Platform with New Tests for IBD Biologics
Prometheus Laboratories launched PredictrPK VDZ and PredictrPK UST, precision-guided dosing tests for vedolizumab and ustekinumab in IBD patients, expanding their platform to cover four major biologics.
TRUST Trial Shows Primary Surgery Improves Progression-Free Survival in Advanced Ovarian Cancer Despite Missing Overall Survival Endpoint
The TRUST trial, the first phase III randomized study comparing surgical timing in advanced ovarian cancer, demonstrated statistically significant improvement in progression-free survival with primary cytoreductive surgery versus interval surgery (22.1 vs 19.7 months, HR=0.80, P=.018).
FDA Expands MenQuadfi Meningococcal Vaccine Approval to Include Infants as Young as 6 Weeks
The FDA approved an expanded indication for Sanofi's MenQuadfi meningococcal vaccine to include children aged 6 weeks to 23 months, making it the only MenACWY vaccine with no upper age limit.
Breakthrough Wireless Device Enables Remote Activation of Light-Sensitive Drugs for Pain Management
Scientists have developed the first wireless device capable of remotely activating photoactivable drugs, demonstrating effective pain management using photolabile morphine without typical opioid side effects.
Pneumonia Antibiotic Piperacillin Shows Promise as Targeted Lyme Disease Treatment at 100-Fold Lower Doses
Northwestern University researchers screened nearly 500 FDA-approved compounds and identified piperacillin as a potentially more effective Lyme disease treatment than current standard doxycycline therapy.
Grove Biopharma Secures $30M Funding, Expands to New R&D Facility in Chicago's Fulton Market
Grove Biopharma, a Northwestern University spinout developing therapies for intracellular disease targets, has secured $30 million in Series A financing to fuel its expansion and research initiatives.
ALS Drug NU-9 Shows Promising Results for Alzheimer's Disease in Animal Study
Northwestern University researchers found that NU-9, an experimental drug approved for ALS clinical trials, effectively reduces toxic protein buildup in Alzheimer's disease animal models.